KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Receivables - Net: 2017-2025

Historic Receivables - Net for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $11.8 million.

  • Aquestive Therapeutics' Receivables - Net rose 21.86% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 21.86%. This contributed to the annual value of $7.3 million for FY2024, which is 13.30% down from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Receivables - Net is $11.8 million, which was down 0.53% from $11.9 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Receivables - Net peaked at $19.9 million during Q1 2022, and registered a low of $4.7 million during Q4 2022.
  • Moreover, its 3-year median value for Receivables - Net was $8.6 million (2023), whereas its average is $9.1 million.
  • Per our database at Business Quant, Aquestive Therapeutics' Receivables - Net tumbled by 62.05% in 2023 and then soared by 97.80% in 2025.
  • Over the past 5 years, Aquestive Therapeutics' Receivables - Net (Quarterly) stood at $12.1 million in 2021, then tumbled by 61.19% to $4.7 million in 2022, then soared by 80.08% to $8.5 million in 2023, then decreased by 13.30% to $7.3 million in 2024, then grew by 21.86% to $11.8 million in 2025.
  • Its Receivables - Net stands at $11.8 million for Q3 2025, versus $11.9 million for Q2 2025 and $10.4 million for Q1 2025.